Title of article :
Invasive Pulmonary Aspergillosis in Patients with Non-Decompensated Liver Cirrhosis: A Case Report
Author/Authors :
Ghasemian، Roya نويسنده Department of Infectious Diseases and Tropical Medicine, Mazandaran University of Medical Sciences, Sari, Iran Ghasemian, Roya , Nosrati، Anahita نويسنده Department of pathology, Emam Hospital, Mazandaran University of Medical Science, Sari, Iran. , , Nabili، Mojtaba نويسنده Department of Medical Mycology and Parasitology/Invasive Fungal Research Centre (IFRC), School of Medicine Mazandaran University of Medical Sciences, , , Shokohi، Tahereh نويسنده ,
Issue Information :
فصلنامه با شماره پیاپی سال 2016
Abstract :
Introduction: Invasive pulmonary aspergillosis (IPA) is a fatal disease usually occurring in patients with neutropenia resulted from
chemotherapy for malignancy. The other risk factors include consuming corticosteroids, organ transplant and advanced acquired
immunodeficiency syndrome (AIDS). Recently, the incidence of IPA in immunocompetent patients without any history of organ
transplant or malignancy has been increasing. Patients with advanced cirrhosis are one of the cases involved in this infection.
Case Presentation: In this case study, we report invasive pulmonary aspergillosis in a 50-year-old patient (from Sari, Iran), who had
gradual abdominal pain and ascites, cough and respiratory distress. Radiographic signs showed a round infiltration in the upper
part of the right lung. Despite receiving 48-hour antibiotics therapy, the fever had not subsided. In CT-guided needle lung biopsy,
septate and acutely angled hyphae (dichotomous) were seen. In CT-guided needle lung biopsy, septate and acutely angled hyphae
(dichotomous) were seen. Direct examination of the sputum showed septate hyphae compatible with a filamentous fungus. According
to morphologicalandmolecular characterization, Aspergillus fumigatuswasconfirmed. Minimuminhibitory concentration
(MIC) values of antifungal agents were determined based on the clinical and laboratory standard institute (CLSI) M38-A2. Treatment
with intravenous amphotericin B was changed to oral voriconazole 200 mg, twice a day. The patient did not have any kind of residual
lung lesion within the six-month follow-up and the cirrhosis was under control and she currently has no respiratory symptoms
or signs.
Conclusions: In patients with liver cirrhosis, when there is evidence of severe pulmonary disease without proper response to treatment,
the possibility of invasive pulmonary fungal infection should be considered.
Journal title :
Archives of Clinical Infectious Diseases
Journal title :
Archives of Clinical Infectious Diseases